The Shotlee Journal
Browse Shotlee articles about Mounjaro.
Showing 9 / 799 Mounjaro articles
Researchers from UCL and the University of Cambridge warn that Ozempic and Wegovy users risk nutritional deficiencies and muscle loss without proper dietary guidance. A study in Obesity Reviews reveals limited evidence on nutrition alongside GLP-1 drugs like semaglutide and tirzepatide. Experts urge structured support to ensure safe, sustainable weight loss.
Cardiologist Dmitry Yaranov states GLP-1 drugs like Ozempic, Wegovy, and Mounjaro offer benefits far beyond weight loss. They enhance cardiovascular health, combat fatty liver disease, and improve blood sugar control in diabetes patients. These medications could redefine treatment for heart, liver, and metabolic diseases.
A woman who shed over four stone on Mounjaro regained weight rapidly after quitting due to overwhelming food noise. She returned to the drug at 5mg, committing to £200 monthly for life to sustain her size 12 figure. Her story highlights GLP-1 challenges in long-term weight management.
Bollywood actress Bhumi Pednekar lost 40kg without Ozempic or injectables, despite constant rumors. She attributes her transformation to disciplined workouts, a balanced vegetarian diet, and recovery from severe dengue. Discover her practical tips for real weight management.
Weight loss drugs like GLP-1 medications are transforming consumer spending patterns. New Circana research reveals users cut grocery costs by 2% but increase outlays on beauty and self-care items. Protein-focused products surge 40% as users combat muscle loss side effects.
Hims & Hers investment narrative shifts amid legal scrutiny on compounded GLP-1 agonists. A January 2026 antitrust lawsuit accuses Eli Lilly and Novo Nordisk of blocking compounded Mounjaro and Wegovy. This raises uncertainties for telehealth providers reliant on these affordable weight management options.
GLP-1 medications are revolutionizing not just weight loss but how people approach food, prioritizing protein quality over quantity. Research shows users eat less overall, including less meat, yet value nutrient-dense proteins more highly. These changes signal premiumization in the food sector and broader economic impacts. (~198 chars)
An analysis of public data shows that pharmaceutical firms paid over $533,000 to Indiana healthcare professionals in 2024 for speaking about GLP-1 medications. The funds covered travel and expenses for conferences. Experts discuss potential influences on prescribing practices, while doctors defend the educational value.
The Food and Drug Administration announced on Tuesday its desire to remove suicide warning labels from GLP-1 weight-loss medications. A comprehensive review of 91 trials revealed no heightened risk of suicidal thoughts or behaviors among users compared to placebo groups. This change aligns the labels with those of diabetes equivalents from the same manufacturers.
